As the EU patent expires on its flagship respiratory diseases product, Spiriva, Boehringer Ingelheim is looking to newer diabetes and respiratory drugs under the leadership of a new CEO.
2 GRIAC Research Institute, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands Correspondence to Loes E M Kistemaker, Department of Molecular Pharmacology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback